Recent developments center on the Trump administration’s April 2026 order, which moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III effective April 28, while leaving broader botanical marijuana in Schedule I. An expedited DEA administrative hearing on the full proposed rescheduling to Schedule III opened June 29 and concluded no later than July 15, 2026, following a December 2025 executive order directing rapid completion of the rulemaking. Trader consensus, reflected in current Polymarket pricing, points to December 31 as the leading outcome at 27 percent, with September 30 at 14 percent, underscoring uncertainty over the remaining steps of an administrative law judge recommendation, DEA final action, and Federal Register publication. Key variables include the hearing record’s influence on timelines and any procedural delays typical of Controlled Substances Act proceedings. No further public milestones are currently scheduled within the resolution window.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于$791,956 交易量
2026-03-31
9月30日
14%
12月31日
27%
$791,956 交易量
9月30日
$0 交易量
14%
12月31日
$182,385 交易量
27%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.Recent developments center on the Trump administration’s April 2026 order, which moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III effective April 28, while leaving broader botanical marijuana in Schedule I. An expedited DEA administrative hearing on the full proposed rescheduling to Schedule III opened June 29 and concluded no later than July 15, 2026, following a December 2025 executive order directing rapid completion of the rulemaking. Trader consensus, reflected in current Polymarket pricing, points to December 31 as the leading outcome at 27 percent, with September 30 at 14 percent, underscoring uncertainty over the remaining steps of an administrative law judge recommendation, DEA final action, and Federal Register publication. Key variables include the hearing record’s influence on timelines and any procedural delays typical of Controlled Substances Act proceedings. No further public milestones are currently scheduled within the resolution window.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
市场开放时间： Feb 7, 2026, 5:04 PM ET
交易量
$791,956结束日期
2026-03-31市场开放时间
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.Recent developments center on the Trump administration’s April 2026 order, which moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III effective April 28, while leaving broader botanical marijuana in Schedule I. An expedited DEA administrative hearing on the full proposed rescheduling to Schedule III opened June 29 and concluded no later than July 15, 2026, following a December 2025 executive order directing rapid completion of the rulemaking. Trader consensus, reflected in current Polymarket pricing, points to December 31 as the leading outcome at 27 percent, with September 30 at 14 percent, underscoring uncertainty over the remaining steps of an administrative law judge recommendation, DEA final action, and Federal Register publication. Key variables include the hearing record’s influence on timelines and any procedural delays typical of Controlled Substances Act proceedings. No further public milestones are currently scheduled within the resolution window.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
交易量
$791,956结束日期
2026-03-31市场开放时间
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...Recent developments center on the Trump administration’s April 2026 order, which moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III effective April 28, while leaving broader botanical marijuana in Schedule I. An expedited DEA administrative hearing on the full proposed rescheduling to Schedule III opened June 29 and concluded no later than July 15, 2026, following a December 2025 executive order directing rapid completion of the rulemaking. Trader consensus, reflected in current Polymarket pricing, points to December 31 as the leading outcome at 27 percent, with September 30 at 14 percent, underscoring uncertainty over the remaining steps of an administrative law judge recommendation, DEA final action, and Federal Register publication. Key variables include the hearing record’s influence on timelines and any procedural delays typical of Controlled Substances Act proceedings. No further public milestones are currently scheduled within the resolution window.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于
警惕外部链接哦。
警惕外部链接哦。
常见问题